DataFollicular lymphoma

Direct links plus the targets, companies, and technologies of this cancer's products.

• Living with follicular lymphoma, the decisions and the people who make them: This is orientation from public patient pages, guidelines and the trials themselves, not advice for your case: your own team's instructions and the 24-hour number they gave you come first, and no figure here is a prediction about you. The decision records, the question sets, the first 60 days checklist and the red cards on this page were written from the NHS, Lymphoma Action, Macmillan and Cancer Research UK patient pages, from NICE NG52, NG47, CG151 and NG234, from the NHS Breast Screening Programme protocols and the Green Book, and from the trial reports named beside each figure, all read on 1 October 2026.
• On being told nobody will treat it. Lymphoma Action's page on active monitoring is the best patient-facing account of this in English and is quoted at length in the decision record, including a person on monitoring describing it as counter-intuitive and a psychological rather than a physical challenge. The randomised evidence behind the approach is a British-led trial of 379 people with asymptomatic, non-bulky, advanced follicular lymphoma, in which early rituximab delayed the need for chemotherapy or radiotherapy without a difference in overall survival.

The same record for scripts and assistants; checked 2026-09-08. Data CC BY-NC 4.0, attribute “Data from OnCo (onco.cc)”.